Nature Communications (Feb 2022)
Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
- Paul F. Lebeau,
- Jae Hyun Byun,
- Khrystyna Platko,
- Paul Saliba,
- Matthew Sguazzin,
- Melissa E. MacDonald,
- Guillaume Paré,
- Gregory R. Steinberg,
- Luke J. Janssen,
- Suleiman A. Igdoura,
- Mark A. Tarnopolsky,
- S. R. Wayne Chen,
- Nabil G. Seidah,
- Jakob Magolan,
- Richard C. Austin
Affiliations
- Paul F. Lebeau
- Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe’s Hamilton and the Hamilton Center for Kidney Research
- Jae Hyun Byun
- Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe’s Hamilton and the Hamilton Center for Kidney Research
- Khrystyna Platko
- Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe’s Hamilton and the Hamilton Center for Kidney Research
- Paul Saliba
- Department of Biochemistry and Biomedical Sciences, McMaster University
- Matthew Sguazzin
- Department of Biochemistry and Biomedical Sciences, McMaster University
- Melissa E. MacDonald
- Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe’s Hamilton and the Hamilton Center for Kidney Research
- Guillaume Paré
- Population Health Research Institute, McMaster University
- Gregory R. Steinberg
- Department of Biochemistry and Biomedical Sciences, McMaster University
- Luke J. Janssen
- Firestone Institute for Respiratory Health, St. Joseph’s Hospital
- Suleiman A. Igdoura
- Department of Biology and Pathology, McMaster University
- Mark A. Tarnopolsky
- Department of Medicine/Neurology, McMaster University
- S. R. Wayne Chen
- Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary
- Nabil G. Seidah
- Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, affiliated to the University of Montreal
- Jakob Magolan
- Department of Biochemistry and Biomedical Sciences, McMaster University
- Richard C. Austin
- Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe’s Hamilton and the Hamilton Center for Kidney Research
- DOI
- https://doi.org/10.1038/s41467-022-28240-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Caffeine may reduce cardiovascular disease risk, but the underlying mechanisms for these effects are incompletely understood. Here the authors report that caffeine inhibits the activation of the transcription factor SREBP2 to promote LDLc clearance through the PCSK9-LDLR axis.
